Both tumor hypoxia and the number of TSD+ EpCAM+/ABCG2+ CSCs were increased significantly in the cisplatin++ group between the 2nd and 8th weeks of tumor growth (Figures 8F–G). This evidence concerns the gene ABCG2 and neoplasm.